Bristol Myers Squibb Signs US$1 B+ Deal with Tubulis for Solid Tumour ADCs
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 4 (Table of Contents)
Published: 27 Apr-2023
DOI: 10.3833/pdr.v2023.i4.2780 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to strengthen its antibody-drug conjugate (ADC) pipeline, Bristol Myers Squibb (BMS) has entered into an agreement with German biotech, Tubulis, to develop next-generation ADCs for the treatment of solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS